Fred Alger Management LLC Makes New $256,000 Investment in United Therapeutics Corporation $UTHR

Key Points

• Fred Alger Management LLC invested approximately $256,000 in United Therapeutics Corporation during the first quarter, purchasing 832 shares of the biotech company.
• Equities analysts have recently increased their price targets on United Therapeutics stock, with target prices ranging from $414.00 to $575.00, indicating a generally positive outlook on the company.
• United Therapeutics reported earnings of $6.41 per share for the last quarter, missing analysts' estimates but showing a 11.7% increase in revenue year-over-year.

Fred Alger Management LLC bought a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 832 shares of the biotechnology company's stock, valued at approximately $256,000.

Other hedge funds have also recently modified their holdings of the company. SVB Wealth LLC bought a new position in shares of United Therapeutics during the 1st quarter worth approximately $32,000. Sound Income Strategies LLC bought a new position in shares of United Therapeutics during the 1st quarter worth approximately $49,000. Brooklyn Investment Group lifted its position in shares of United Therapeutics by 103.2% during the 1st quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company's stock worth $59,000 after buying an additional 98 shares in the last quarter. WPG Advisers LLC bought a new position in shares of United Therapeutics during the 1st quarter worth approximately $60,000. Finally, State of Wyoming bought a new position in shares of United Therapeutics during the 4th quarter worth approximately $62,000. Institutional investors own 94.08% of the company's stock.

Analyst Ratings Changes

Several equities analysts have commented on UTHR shares. HC Wainwright lifted their target price on shares of United Therapeutics from $400.00 to $500.00 and gave the stock a "buy" rating in a research report on Friday, September 5th. Oppenheimer raised their price target on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an "outperform" rating in a research note on Friday, September 5th. Morgan Stanley decreased their price target on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research note on Thursday, July 10th. UBS Group raised their price target on shares of United Therapeutics from $415.00 to $560.00 and gave the stock a "buy" rating in a research note on Thursday, September 4th. Finally, Wells Fargo & Company raised their price target on shares of United Therapeutics from $295.00 to $414.00 and gave the stock an "equal weight" rating in a research note on Wednesday, September 3rd. Nine investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, United Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $438.85.

United Therapeutics Price Performance

Shares of UTHR stock opened at $396.50 on Thursday. The company's fifty day simple moving average is $314.12 and its two-hundred day simple moving average is $306.91. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $436.95. The stock has a market capitalization of $17.89 billion, a price-to-earnings ratio of 15.48, a PEG ratio of 6.16 and a beta of 0.62.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. During the same period in the previous year, the firm earned $5.85 EPS. The company's revenue was up 11.7% compared to the same quarter last year. Equities research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $385.21, for a total transaction of $4,237,310.00. Following the sale, the executive vice president owned 36,781 shares of the company's stock, valued at $14,168,409.01. The trade was a 23.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Jan Malcolm sold 700 shares of the business's stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $400.29, for a total transaction of $280,203.00. Following the sale, the director directly owned 520 shares in the company, valued at $208,150.80. The trade was a 57.38% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 124,816 shares of company stock worth $44,247,193. Company insiders own 10.30% of the company's stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.